Novo Nordisk A/S (Novo Nordisk A/S) Accumulated other comprehensive income (loss) : $187 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Novo Nordisk A/S's Accumulated other comprehensive income (loss) for the quarter that ended in Dec. 2023 was $187 Mil.

Novo Nordisk A/S's quarterly Accumulated other comprehensive income (loss) declined from Jun. 2023 ($278 Mil) to Sep. 2023 ($116 Mil) but then increased from Sep. 2023 ($116 Mil) to Dec. 2023 ($187 Mil).

Novo Nordisk A/S's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 ($-260 Mil) to Dec. 2022 ($349 Mil) but then declined from Dec. 2022 ($349 Mil) to Dec. 2023 ($187 Mil).

Novo Nordisk A/S Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Novo Nordisk A/S's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Accumulated other comprehensive income (loss) Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated other comprehensive income (loss)

Get a 7-Day Free Trial

-103.23

-148.97

-260.45

348.72

186.69

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accumulated other comprehensive income (loss)	Get a 7-Day Free Trial															348.72	338.60	277.51	115.92	186.69

Novo Nordisk A/S Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Novo Nordisk A/S Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.